FGFR2 fusion / activating mutation in metastatic urothelial carcinoma: erdafitinib (BLC20...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR2-MUTATION-UROTHELIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-CIVIC SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Actionability Facts
| Biomarker | BIO-FGFR2 |
|---|---|
| Variant | activating mutation (FGFR2 fusion or kinase-domain mutation) |
| Disease | DIS-UROTHELIAL |
| ESCAT tier | IB |
| Recommended combinations | erdafitinib monotherapy (2L+ post-platinum / post-IO) |
| Evidence summary | FGFR2 fusion / activating mutation in metastatic urothelial carcinoma: erdafitinib (BLC2001, Loriot NEJM 2019 — ORR 40%; THOR phase 3, Loriot NEJM 2023 — OS HR 0.64 vs chemo) is FDA-approved for FGFR2/3-altered locally advanced or metastatic urothelial 2L+. FGFR2 alterations less common than FGFR3 in urothelial (~3% vs ~15%). |
Notes
ESCAT IB. OncoKB Level 1. FDA companion diagnostic: therascreen FGFR RGQ RT-PCR (covers FGFR2 fusions and FGFR3 mut/fusions). Detection: RNA-NGS preferred for fusions. Hyperphosphatemia is on-target toxicity requiring dose modification.
Used By
No reverse references found in the YAML corpus.